Stock listing
Bioversys Ag
Selected listing: BIOV · SIX · CHF · CH
Bioversys Ag (SIX Swiss: BIOV), Health Technology. Latest release Sep 9, 2026: BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial…
- Ticker
- SIX Swiss: BIOV
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- SIX Swiss
- Currency
- CHF
About Bioversys Ag
Bioversys Ag is a public company based in Switzerland, trading under the ticker BIOV. Bioversys focuses on developing innovative solutions in the biotechnology sector.
Latest news from Bioversys Ag
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
September 9, 2026
BioVersys to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
BioVersys granted Fast-Track Designation from US FDA for BV100
September 2, 2026
BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call
August 26, 2026
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
April 30, 2026